<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> is used in the treatment of patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, who develop <z:mp ids='MP_0005048'>thrombosis</z:mp> while being managed on oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Although laboratory monitoring of this agent is not widely performed, it has been suggested to be useful in selected situations of high-risk <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>It is however not entirely clear, whether the dose should be altered on the basis of anti-Xa results in asymptomatic individuals </plain></SENT>
</text></document>